UPXI on Nasdaq
UPEXI, INC.
We are in the cryptocurrency industry and the management of cash assets through a cryptocurrency portfolio, primarily focused in Solana tokens and generating a yield from the treasury, primarily.5 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Forward Industries, Inc., BTCS Inc. or OpenWorld, Inc., or pick any stock.
- TickerUPXI on Nasdaq2
- IndustryFinance Services2
- HeadquartersTampa, United States2
- Incorporated inDE4
- Business address3030 N. Rocky Point Drive, Suite 420, Tampa, Fl4
- Filer categoryNon-accelerated filer, Smaller reporting company4
- Legal formCorporation2
- LEI529900DXT4FO60PCDE092
- StatusActive2
- LEI statusIssued and current2
- Registered addressc/o VCORP AGENT SERVICES, INC.,108 W. 13TH STREET SUITE 100, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 102442672
See how the biggest companies compare on our leaderboards
We are in the cryptocurrency industry and the management of cash assets through a cryptocurrency portfolio, primarily focused in Solana tokens and generating a yield from the treasury, primarily through staking of those tokens. We continue to be brand owners, selling our products wholesale and direct to consumers. Distribution and fulfillment of our products is done by a third-party specializing in these services.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue15¢$2.6M
- Other costs85¢$14.7M
- Interest0¢$62.7K
Out of $17.4M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Revenue | $7.6M | $14.8M |
| Digital asset revenue | $17.4M | $985.0K |
| Total revenue | $25.0M | $15.8M |
| Cost of revenue | $2.6M | $4.9M |
| Gross profit | $22.4M | $10.9M |
| Sales and marketing | $2.9M | $4.0M |
| Distribution costs | $2.6M | $4.7M |
| General and administrative | $26.4M | $11.9M |
| Unrealized loss (gain) on digital assets | $195.1M | -$105.5K |
| Realized loss on digital asset revenue conversion to USD | $4.9M | $0 |
| Realized loss on sale of digital assets | $6.8M | $0 |
| Stock-based compensation | $21.9M | $2.4M |
| Amortization of acquired intangible assets | $76.8K | $76.8K |
| Impairment on assets from manufacturing shut down | $1.4M | $0 |
| Impairment on acquired intangible assets | $750.0K | $0 |
| Depreciation | $379.5K | $681.0K |
| Lease Impairment (gain on settlement), Delray Beach facility | $0 | -$270.0K |
| Total operating expenses | $263.2M | $23.4M |
| Loss from operations | -$240.8M | -$12.5M |
| Interest expense, net | -$13.6M | -$1.2M |
| Gain on extinguishment of debt | $10.3M | $0 |
| Other expense, net | -$1.9M | -$10.7K |
| Other expense, net | -$5.2M | -$1.2M |
| Loss on operations before income tax | -$246.1M | -$13.7M |
| Income tax benefit (expense) | $0 | $0 |
| Net loss | -$246.1M | -$13.7M |
| Loss per share | -$3.87 | -$1.73 |
| Loss per share | -$3.87 | -$1.73 |
| Basic weighted average shares outstanding | 63.5M shares | 7.9M shares |
| Fully diluted weighted average shares outstanding | 63.5M shares | 7.9M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Cash | $5.8M | $3.0M | $661.4K |
| Accounts receivable, net | $97.2K | $157.5K | |
| Inventory, net | $266.0K | $1.2M | |
| Due from VitaMedica transition | $10.8K | $228.0K | |
| Prepaid expenses and other assets | $988.5K | $350.8K | |
| Current digital assets at fair value | $109.6M | $49.9M | |
| Purchase price receivable - VitaMedica | $0 | $2.0M | |
| Total current assets | $116.8M | $56.8M | |
| Property and equipment, net | $208.0K | $2.1M | |
| Intangible assets, net | $86.4K | $163.1K | |
| Goodwill | $673.9K | $848.9K | |
| Deferred tax asset | $5.9M | $5.9M | |
| Digital assets at fair value, net of current | $55.7M | $56.1M | |
| Other assets | $163.2K | $192.1K | |
| Right-of-use asset, net | $598.7K | $1.7M | |
| Total noncurrent assets | $63.4M | $67.0M | |
| Total assets | $180.1M | $123.8M | |
| Accounts payable | $277.6K | $1.0M | |
| Accrued compensation | $5.3M | $3.5M | |
| Deferred revenue | $4.5K | $13.2K | |
| Accrued liabilities | $1.7M | $356.1K | |
| Accrued interest | $2.3M | $792.4K | |
| Acquisition payable | $260.7K | $260.7K | |
| Current portion of promissory notes | $0 | $560.0K | |
| Short-term treasury debt | $57.3M | $20.0M | |
| Current portion of Cygnet subsidiary notes payable | $3.7M | $5.4M | |
| Current portion of operating lease payable | $295.2K | $691.0K | |
| Total current liabilities | $71.1M | $32.6M | |
| Operating lease payable, net of current portion | $362.2K | $1.1M | |
| Convertible notes payable | $162.4M | $0 | |
| Total long-term liabilities | $162.8M | $1.1M | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 shares issued and outstanding | $2 | $2 | |
| Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 78,702,358 and 38,270,571 shares issued and outstanding, as of June 30, 2026 and June 30, 2025, respectively | $787 | $383 | |
| Additional paid in capital | $252.8M | $150.6M | |
| Accumulated deficit | -$306.6M | -$60.5M | |
| Total stockholders' equity | -$53.8M | $90.1M | $6.5M |
| Total liabilities and stockholders' equity | $180.1M | $123.8M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 150.0K shares | 150.0K shares | |
| Preferred stock, shares outstanding | 150.0K shares | 150.0K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.0B shares | 1.0B shares | |
| Common stock, shares issued | 78.7M shares | 38.3M shares | |
| Common stock, shares outstanding | 78.7M shares | 38.3M shares |
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Cash | $5.8M | $3.0M | $661.4K |
| Accounts receivable, net | $97.2K | $157.5K | |
| Inventory, net | $266.0K | $1.2M | |
| Due from VitaMedica transition | $10.8K | $228.0K | |
| Prepaid expenses and other assets | $988.5K | $350.8K | |
| Current digital assets at fair value | $109.6M | $49.9M | |
| Purchase price receivable - VitaMedica | $0 | $2.0M | |
| Total current assets | $116.8M | $56.8M | |
| Property and equipment, net | $208.0K | $2.1M | |
| Intangible assets, net | $86.4K | $163.1K | |
| Goodwill | $673.9K | $848.9K | |
| Deferred tax asset | $5.9M | $5.9M | |
| Digital assets at fair value, net of current | $55.7M | $56.1M | |
| Other assets | $163.2K | $192.1K | |
| Right-of-use asset, net | $598.7K | $1.7M | |
| Total noncurrent assets | $63.4M | $67.0M | |
| Total assets | $180.1M | $123.8M | |
| Accounts payable | $277.6K | $1.0M | |
| Accrued compensation | $5.3M | $3.5M | |
| Deferred revenue | $4.5K | $13.2K | |
| Accrued liabilities | $1.7M | $356.1K | |
| Accrued interest | $2.3M | $792.4K | |
| Acquisition payable | $260.7K | $260.7K | |
| Current portion of promissory notes | $0 | $560.0K | |
| Short-term treasury debt | $57.3M | $20.0M | |
| Current portion of Cygnet subsidiary notes payable | $3.7M | $5.4M | |
| Current portion of operating lease payable | $295.2K | $691.0K | |
| Total current liabilities | $71.1M | $32.6M | |
| Operating lease payable, net of current portion | $362.2K | $1.1M | |
| Convertible notes payable | $162.4M | $0 | |
| Total long-term liabilities | $162.8M | $1.1M | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 shares issued and outstanding | $2 | $2 | |
| Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 78,702,358 and 38,270,571 shares issued and outstanding, as of June 30, 2026 and June 30, 2025, respectively | $787 | $383 | |
| Additional paid in capital | $252.8M | $150.6M | |
| Accumulated deficit | -$306.6M | -$60.5M | |
| Total stockholders' equity | -$53.8M | $90.1M | $6.5M |
| Total liabilities and stockholders' equity | $180.1M | $123.8M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 150.0K shares | 150.0K shares | |
| Preferred stock, shares outstanding | 150.0K shares | 150.0K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.0B shares | 1.0B shares | |
| Common stock, shares issued | 78.7M shares | 38.3M shares | |
| Common stock, shares outstanding | 78.7M shares | 38.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net loss | -$246.1M | -$13.7M |
| Depreciation and amortization | $456.2K | $757.8K |
| Unrealized loss (gain) on digital assets | $195.1M | -$101.3K |
| Realized loss on sale of digital assets | $6.8M | $0 |
| Digital asset revenue | -$17.4M | -$985.0K |
| Digital asset revenue conversion to USD | $13.2M | $0 |
| Realized loss on digital asset revenue conversion to USD | $4.9M | $0 |
| Amortization of loan costs | $3.7M | $30.5K |
| Loss on disposal of property and equipment | $237.7K | $10.7K |
| Gain on extinguishment of debt | -$10.3M | $0 |
| Inventory write-off | $0 | $748.9K |
| Bad debt reserve for Amazon receivable | $0 | $934.0K |
| Reduction of acquisition payable | $0 | -$152.5K |
| Lease impairment (gain on settlement) | $0 | -$270.0K |
| Impairment on assets from manufacturing shut down | $1.4M | $0 |
| Impairment on acquired intangible assets | $750.0K | $0 |
| Issuance of stock for services | $0 | $250.0K |
| Stock-based compensation | $21.9M | $2.1M |
| Accounts receivable | $60.3K | -$484.6K |
| Inventory | $886.9K | -$470.2K |
| Prepaid expenses and other assets | -$411.6K | $222.0K |
| Operating lease payable | -$26.7K | $21.0K |
| Accounts payable and accrued liabilities | $4.0M | $2.9M |
| Deferred revenue | -$8.6K | -$222.1K |
| Net cash used in operating activities | -$21.0M | -$8.4M |
| Proceeds from the sale of building | $0 | $4.0M |
| Proceeds from the sale of E-core | $0 | $2.0M |
| Proceeds from the sale of MW Products assets | $175.0K | $0 |
| Proceeds from the sale of VitaMedica, Inc. | $2.0M | $0 |
| Acquisition of digital assets | -$40.0M | -$104.9M |
| Proceeds from the sale of digital assets | $8.0M | $0 |
| Acquisition of royalty interest | -$750.0K | $0 |
| Acquisition of property and equipment | -$44.0K | -$387.8K |
| Net cash used in investing activities | -$30.6M | -$99.3M |
| Proceeds from issuance of common stock | $75.2M | $92.6M |
| Issuance of preferred stock series A | $0 | $325.0K |
| Proceeds from exercise of warrants | $107.9K | $250.0K |
| Repurchases of common stock | -$2.8M | $0 |
| Proceeds from short-term treasury debt | $5.0M | $0 |
| Repayment of short-term treasury debt | -$10.4M | $0 |
| Proceeds from issuance of convertible notes | $0 | $350.0K |
| Repayment of promissory notes | -$560.0K | $0 |
| Proceeds from related party advance | $0 | $75.0K |
| Repayment of related party advance | $0 | -$175.0K |
| Payments of equity issuance costs | -$4.5M | $0 |
| Payments of debt issuance costs | -$7.6M | $0 |
| Payment on acquisition notes payable | $0 | -$66.7K |
| Payment on convertible note | $0 | -$150.0K |
| Proceeds from issuance of short-term debt | $0 | $20.0M |
| Repayment of related party note payable | $0 | -$500.0K |
| Repayment on note payable on building | $0 | -$2.6M |
| Net cash provided by financing activities | $54.4M | $110.0M |
| Net increase in cash | $2.8M | $2.3M |
| Interest paid | $8.4M | $805.9K |
| Income tax paid | $11.3K | $0 |
| Issuance of common stock for the repayment of convertible notes payable | $12.3M | $1.8M |
| Issuance of convertible debt for digital assets acquired | $187.1M | $0 |
| Issuance of short-term debt for digital assets acquired | $42.7M | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led UPEXI, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerAllan Marshall Jun 24, 2021 to now13
- PresidentRobert Hackett Jun 24, 2021 to Jun 24, 202114
- Chief financial officerAndrew James Norstrud Jun 24, 2021 to now15
Board members and other officers (8)
- CSOBrian Benjamin Rudick Jun 3, 2025 to now16
- Chief Operations OfficerAnthony P. Bazan Sep 8, 2022 to Sep 8, 202217
- Board memberAndrew James Norstrud Apr 25, 2025 to now18
- Board memberAllan Marshall Jun 24, 2021 to now13
- Board memberGene Salkind Jun 24, 2021 to now19
- Board memberLawrence Dugan Jun 24, 2021 to now20
- Board memberRobert Hackett Jun 24, 2021 to Jun 24, 202114
- Board memberThomas Charles Williams Jun 24, 2021 to now21
Named in SEC Form D filings
People the company listed in its private-offering notices.
Former names
- GROVE, INC.Apr 30, 2019 to Aug 16, 20224
Timeline
Filings
348 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 167 major events, 39 insider forms, 28 large holders, 4 private raises, 88 other. The latest 20:
- Oct 13, 20268-K EDGAR
- Oct 13, 2026DEF 14A EDGAR
- Oct 7, 20268-K EDGAR
- Sep 29, 2026PRE 14A EDGAR
- Sep 17, 20268-K EDGAR
- Sep 17, 202610-K EDGAR
- Sep 15, 20268-K EDGAR
- Sep 14, 20268-K EDGAR
- Sep 9, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Jul 31, 2026SCHEDULE 13G/A EDGAR
- Jul 31, 20268-K EDGAR
- Jul 24, 2026SCHEDULE 13G/A EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 16, 2026EFFECT EDGAR
The 348 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
36 open-market trades by officers, directors and large owners since October 2021: 36 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 23, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 50,000 | $1.80 | $90.0K | Form 4 |
| Dec 16, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 50,000 | $2.07 | $103.5K | Form 4 |
| Dec 15, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 100,000 | $2.07 | $207.0K | Form 4 |
| Nov 20, 2025 | Salkind GeneDirector | Buy | 50,000 | $2.55 | $127.5K | Form 4 |
| Nov 17, 2025 | Salkind GeneDirector | Buy | 200,000 | $2.73 | $546.0K | Form 4 |
| Jul 22, 2025 | Dugan LawrenceDirector | Buy | 4,000 | $7.50 | $30.0K | Form 4 |
| Jul 16, 2025 | Dugan LawrenceDirector | Buy | 11,000 | $5.69 | $62.6K | Form 4 |
| Jul 15, 2025 | Dugan LawrenceDirector | Buy | 1,000 | $5.17 | $5.2K | Form 4 |
| Jul 11, 2025 | Salkind GeneDirector | Buy | 20,243 | $4.94 | $100.0K | Form 4 |
| Jul 11, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 161,943 | $4.94 | $800.0K | Form 4 |
| Apr 17, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 657,895 | $2.28 | $1.5M | Form 4 |
| Apr 17, 2025 | Norstrud Andrew JamesChief Financial Officer | Buy | 43,860 | $2.28 | $100.0K | Form 4 |
| Apr 17, 2025 | Salkind GeneDirector | Buy | 241,229 | $2.28 | $550.0K | Form 4 |
| Mar 12, 2024 | MARSHALL ALLANChief Executive Officer | Buy | 64,150 | $0.57 | $36.6K | Form 4 |
| Mar 11, 2024 | MARSHALL ALLANChief Executive Officer | Buy | 13,623 | $0.60 | $8.2K | Form 4 |
| Mar 5, 2024 | MARSHALL ALLANChief Executive Officer | Buy | 103,013 | $0.70 | $72.1K | Form 4 |
| Dec 15, 2023 | MARSHALL ALLANChief Executive Officer | Buy | 4,535 | $0.91 | $4.1K | Form 4 |
| Dec 14, 2023 | MARSHALL ALLANChief Executive Officer | Buy | 8,381 | $0.98 | $8.2K | Form 4 |
| Dec 7, 2023 | MARSHALL ALLANChief Executive Officer | Buy | 90,001 | $0.94 | $84.6K | Form 4 |
| Dec 5, 2023 | MARSHALL ALLANChief Executive Officer | Buy | 19,296 | $0.84 | $16.2K | Form 4 |
All 36 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Hivemind Capital Partners, LLCSCHEDULE 13G/A, 2 filings Aug 14, 202624
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Apr 30, 2026 to Jul 31, 202625
- GSR Growth Investments LPSCHEDULE 13G/A, 4 filings Apr 30, 2025 to Jul 24, 202626
- Polar Asset Management Partners Inc.SCHEDULE 13G/A, 3 filings Nov 14, 2025 to May 15, 202627
- MMCAP International Inc. SPCSCHEDULE 13G/A, 2 filings Jul 22, 2025 to Feb 13, 202628
- Kathmere Capital Management, LLCSCHEDULE 13G/A, 2 filings Jul 30, 2025 to Feb 11, 202629
- Marex Securities Products Inc.SCHEDULE 13G, 1 filing Jan 8, 202630
- Attestor Value Master Fund, LPSCHEDULE 13G, 2 filings Jul 11, 2025 to Oct 16, 202531
- Michael NovogratzSCHEDULE 13G/A, 2 filings May 1, 2025 to Aug 5, 202532
- Robert HackettSC 13G, 2 filings Feb 14, 2022 to Jun 1, 202333
- Allan MarshallSC 13G/A, 2 filings Feb 14, 2022 to Mar 10, 202334
- Andrew James NorstrudSC 13G, 1 filing Mar 10, 202335
- Gene SalkindSC 13G/A, 2 filings Feb 14, 2022 to Mar 10, 202336
- Jeffrey Michael BishopSC 13G, 1 filing Feb 10, 202237
Money raised
Private offerings the company reported to the SEC on Form D.
- Jun 21, 2026Raised $19.5 million in a private offering of securities Form D: 1 investor so far Form D
- Jul 11, 2025Raised $200 million in a private offering of equity Form D: 1 investor so far Form D
- Apr 24, 2025Raised $100 million in a private offering of equity Form D: 73 investors so far Form D
- Oct 19, 2021Raised $4 million in a private offering of equity Form D: 2 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 47. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Arrington Capital Management, LLC | 2,760,107 | $2.2M | 2.4% | No change |
| Vanguard Capital Management LLC | 2,409,720 | $1.9M | 0.0% | −972,882 |
| MMCAP International Inc. SPC | 2,326,777 | $1.8M | 0.2% | No change |
| BlackRock, Inc. | 888,906 | $697.1K | 0.0% | +207,598 |
| Osaic Holdings, Inc. | 770,236 | $600.8K | 0.0% | −5,626 |
| Susquehanna International Group, Llp | 703,129 | $551.4K | 0.0% | +4,401 |
| Geode Capital Management, LLC | 582,895 | $457.4K | 0.0% | +44,378 |
| Vanguard Fiduciary Trust Co | 311,362 | $244.1K | 0.0% | −16,621 |
| Millennium Management LLC | 271,216 | $212.7K | 0.0% | −22,968 |
| UBS Group AG | 232,206 | $182.0K | 0.0% | −533,570 |
| XTX Topco Ltd | 229,653 | $180.1K | 0.0% | +110,199 |
| State Street Corp | 192,022 | $150.6K | 0.0% | No change |
| Jane Street Group, LLC | 191,536 | $150.2K | 0.0% | +841 |
| J. Derek Lewis & Associates Inc. | 125,000 | $98.0K | 0.0% | +28,000 |
| Northern Trust Corp | 117,311 | $92.0K | 0.0% | +9,091 |
| Citadel Advisors LLC | 100,402 | $78.7K | 0.0% | New |
| Citigroup Inc | 79,135 | $62.1K | 0.0% | +79,130 |
| Engineers Gate Manager LP | 77,738 | $61.0K | 0.0% | +24,885 |
| Pinnacle Financial Partners, Inc. | 70,720 | $55.5K | 0.0% | No change |
| Goldman Sachs Group Inc | 68,378 | $53.6K | 0.0% | +46,187 |
| IMC-Chicago, LLC | 52,768 | $41.4K | 0.0% | +4,698 |
| Millington Financial Advisors, LLC | 40,000 | $32.2K | 0.0% | No change |
| Commonwealth Equity Services, LLC | 33,125 | $26.0K | 0.0% | +500 |
| Morgan Stanley | 27,166 | $21.3K | 0.0% | +20,066 |
| Cetera Investment Advisers | 24,207 | $19.0K | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARUPEXI, INC. filings on SEC EDGAR
- 2
- 3SEC EDGARUPEXI, INC. 10-K for fiscal 2026
- 4SEC EDGARUPEXI, INC. filings on SEC EDGAR
- 5
- 6SEC EDGARUPEXI, INC. 10-K for fiscal 2020
- 7SEC EDGARUPEXI, INC. 10-K for fiscal 2021
- 8SEC EDGARUPEXI, INC. 10-K for fiscal 2022
- 9SEC EDGARUPEXI, INC. 10-K for fiscal 2023
- 10SEC EDGARUPEXI, INC. 10-K for fiscal 2024
- 11SEC EDGARUPEXI, INC. 10-Q for fiscal 2025
- 12SEC EDGARUPEXI, INC. 10-Q for fiscal 2026
- 13
- 14SEC EDGARRobert Hackett, President
- 15
- 16SEC EDGARBrian Benjamin Rudick, CSO
- 17
- 18SEC EDGARAndrew James Norstrud, Board member
- 19SEC EDGARGene Salkind, Board member
- 20SEC EDGARLawrence Dugan, Board member
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33SEC EDGARRobert Hackett SC 13G on UPEXI, INC.
- 34
- 35
- 36SEC EDGARGene Salkind SC 13G/A on UPEXI, INC.
- 37